Fig. 8

CD28^± cluster-derived signatures are predictive of response to PD-L1 blockade in advanced NSCLC patients. A, C, E Kaplan–Meier curves depicting the OS probability of adenocarcinoma NSCLC patients from TCGA stratified based on High/Low expression levels of C0 KLRG1⁺EOMES⁺CD28⁺/Adaptive Immunity signature (A), C4 Treg-like T_RM CD28⁻ /Adaptive Immunity signature (C) and C2 KLRC1⁺KLRK1⁺T_RM CD28^- /Adaptive Immunity signature (E). For each signature, three TCGA patient cohorts based on the expression levels of CD8, PD1 and CD28 genes are shown: CD8⁺PD1⁺ (left panels), CD8⁺PD1⁺CD28⁻ (middle panels), CD8⁺PD1⁺CD28⁺ (right panels). Number of patients at risk and P values are shown. Significance was calculated using the log-rank test. B, D, F Barplots showing the percentage of Responder (R) and Non-Responder (NR) patients in two cohorts of the OAK dataset (PD1⁺CD28⁻, left panels; PD1⁺CD28⁺, right panels), stratified for High/Low scores of Adaptive Immunity/C0 signature (n = 14 and n = 37 for PD1⁺CD28⁻ and PD1⁺CD28⁺, respectively) (B), Adaptive Immunity/C4 signature (n = 31 and n = 72 for PD1⁺CD28⁻ and PD1⁺CD28⁺, respectively) (D) and Adaptive Immunity/C2 signature (n = 23 and n = 58 for PD1⁺CD28⁻ and PD1⁺CD28⁺, respectively) (F). P values are shown. Significance was computed using the Fisher’s Exact test